Open Access DOI:10.23937/2474-3658/1510238
Impact of Adding Remdesivir to Tocilizumab in Hospitalized Patients with Coronavirus Disease
Chelsea A Schneider, PharmD, Jenny Martinez, PharmD, Kathleen Jodoin, PharmD and William R Wolowich, PharmD
Article Type: Original Article | First Published: November 25, 2021
Several treatments have been utilized in the management of COVID-19 and only remdesivir is FDA-approved at this time. Tocilizumab is an interleukin-6 antagonist that has controversial data regarding its benefits in hospitalized COVID-19 patients. Remdesivir in addition to tocilizumab has not shown any additive benefit to date; however, randomized controlled trials are in process. The objective of this study was to assess the role of tocilizumab with or without remdesivir in reducing mortality an...
Open Access DOI:10.23937/2474-3658/1510237
Attaining the Balance between Wild Poliovirus Eradication and Vaccine-Derived Poliovirus Control
Emmanuel Ebuka Elebesunu and Confidence Nmesoma Ubani
Article Type: Commentary | First Published: November 11, 2021
Poliomyelitis is one of the leading causes of paralysis among children under five years of age, and has been a major public health threat until recent times when high success rates were attained in poliovirus elimination through massive vaccination campaigns in various regions worldwide. In the course of vaccination, a new trend of vaccine-derived poliovirus occurred, due to genetic reversions in the live attenuated oral polio vaccine that resulted in the emergence of virulent forms. To tackle t...
Open Access DOI:10.23937/2474-3658/1510236
An Unusual Presentation of Disseminated Tuberculosis in South-West Nigeria: A Case Report
Martins Ehizode Emuze, Arinola Esan, Oladotun Olalusi, Omolade O Adegoke, Temitope E Ogunsanya, Chima Akunwata and John Akulue
Article Type: Case Report | First Published: November 11, 2021
Disseminated tuberculosis is a leading cause of morbidity and mortality in developing nations. It could be a diagnostic challenge because of the nonspecific manifestations and sometimes atypical laboratory and radiologic findings. It results from haematogenous spread of Mycobacterium tuberculosis in 2 or more noncontiguous sites. Clinical features may include fever, weight loss, anorexia, anemia, pancytopenia, hepatosplenomegaly and most times, patients have elevated inflammatory markers like er...
Open Access DOI:10.23937/2474-3658/1510234
The Placental Buffer Effect and the Pathophysiology of COVID-19: Possibilities for a Guide Aimed at Pregnant and Postpartum Women Considering Praxis: Theory, Clinical and Laboratory Observation
Luiz Gonzaga Francisco de Assis Barros D’Elia Zanella, MD iD and Miriane Marques Borges, MD
Article Type: Review/Hypothesis | First Published: November 05, 2021
SARS-CoV-2 causes placental changes that can lead to embryonic/foetal death. However, the pregnant woman who in other diseases is considered (e.g., H1N1) a risk group for the development of severe forms of the disease, in COVID-19 rarely evolves with severity, except when childbirth occurs, and the woman loses the bond with the placenta. The answer for the pregnant woman is in the immunosuppression promoted by the placenta, in the metabolism of tryptophan and phenylalanine (Try) and functions of...
